Direct Acting Anti-Viral's In Chronic HCV Patients

The cross sectional survey data will be collected on a pre-defined questionnaire from Gastroenterologist and Hepatologist. The questionnaire will provide us information on demographics, relevant patient history, concomitant medication, ongoing treatment plan recommended for chronic HCV and adverse event details.

The questions related to Pharmacovigilance and safety assessment includes the International Nonproprietary Names (INN) unless it is prescribed brand of Getz Pharma. All adverse events associated with the prescribed treatment will be recorded. Data on outcome assessment will be based on action taken due to AE and other reported details. Seriousness of adverse event will also be recorded as per the ICH classification and severity of medical event will be assessed as per Karch and Lasagna classification.

All the information will be recorded by the healthcare professionals on the questionnaire during direct interaction with the patients.

Patients' written authorization to use and/or disclose the patient's personal and/or health data will be obtained. However, patient data secrecy will follow ICH GCP requirements.

Inclusion criteria

• Written informed consent
• Male or Female patient
• Age of patient ≥18 years
• Patients already diagnosed with HCV and on DAAs therapy.

Exclusion criteria

• Written informed consent
• Male or Female patient
• Age of patient ≥18 years
• Patients already diagnosed with HCV and on DAAs therapy.